Our Publications

“Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors”
February 2023
“Implications of T cell receptor biology on the development of new T cell therapies for cancer.”
January 2020
“Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.”
Nature Communications.
May 2019
“Synthetic T cell receptor-based lymphocytes for cancer therapy.”
Advanced Drug Delivery Reviews.
February 2019
“Preclinical evaluation of mesothelin-specific T cell receptor (TCR) fusion constructs (TRuC™s) utilizing the signaling power of the complete TCR complex: A new opportunity for solid tumor therapy.”
Cancer Research.
July 2018
“Characterization of a novel class of engineered (TCR) fusion constructs (TRuC™s) aimed to treat solid tumors.”
Cancer Research.
July 2018
“Novel T Cell Receptor Fusion Constructs TRuC TM Polypeptides Utilizing the Signaling Power of the Complete TCR Complex for Solid Tumor Therapy.”
Molecular Therapy.
May 2018
“Characterization of Mesothelin-Specific T Cell Receptor Fusion Construct (TRuC TM) Expressing T Cells for the Treatment of Solid Tumors.”
Molecular Therapy.
May 2018

Reference Publications

“Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy.”
JAMA Oncology.
December 2018
“Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.”
Clinical Cancer Research.
June 2018
“CAR-T Therapies: Final Evidence Report.”
Institute for Clinical and Economic Review.
March 2018
“Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.”
New England Journal of Medicine.
February 2018
“Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.”
New England Journal of Medicine.
December 2017
“Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3.”
Journal of Clinical Oncology.
October 2017
“Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.”
Clinical cancer research.
September 2017
“Mitochondrial dynamics controls T cell fate through metabolic programming.”
June 2016
“Toxicity and management in CAR T-cell therapy.”
Molecular Therapy-Oncolytics.
April 2016
“Making better chimeric antigen receptors for adoptive T-cell therapy.”
Clinical Cancer Research.
April 2016
“The urgent need to recover MHC class I in cancers for effective immunotherapy.”
Current Opinion in Immunology.
April 2016
“Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.”
Clinical Cancer Research.
February 2014
“MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.”
Journal of the National Cancer Institute.
August 2013
“Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.”
Nature Immunology.
March 2013
“TCR signaling emerges from the sum of many parts.”
Frontiers in Immunology.
June 2012
“Full activation of the T cell receptor requires both clustering and conformational changes at CD3.”
January 2007
“HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.”
Molecular Medicine Today.
April 1999

This page contains links to sites at which articles written by persons not affiliated with TCR² are available for purchase. The third-party articles referenced in this Publications section are identified for background purposes only, and TCR² does not purport that they represent a complete survey of the relevant science. The views expressed in the articles are those of their respective authors and do not reflect the views of TCR². TCR² has not independently verified any of the information contained in the third-party articles and disavows any obligation to update or correct the information contained in these articles.

Scientific Posters

Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuC™) T cells
Preliminary safety and efficacy ofgavocabtageneautoleucel(gavo-cel,TC-210), a T cell receptor fusion construct (TRuC™), in patients with treatment refractory mesothelin overexpressing solid tumors
Discovery and Preclinical Characterization of Fratricide-Resistant TRuC™-T Cells Targeting CD70
Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuC™) T cells